179 related articles for article (PubMed ID: 37036488)
1. Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy.
Ruan M; Wang H; Li X; Song G
Abdom Radiol (NY); 2023 Jun; 48(6):2139-2147. PubMed ID: 37036488
[TBL] [Abstract][Full Text] [Related]
2. Clinically significant prostate cancer (csPCa) detection with various prostate sampling schemes based on different csPCa definitions.
Wang F; Chen T; Wang M; Chen H; Wang C; Liu P; Liu S; Luo J; Ma Q; Xu L
BMC Urol; 2021 Dec; 21(1):183. PubMed ID: 34949183
[TBL] [Abstract][Full Text] [Related]
3. Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?
Liu H; Ruan M; Wang H; Wang H; Li X; Song G
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):589-595. PubMed ID: 32719353
[TBL] [Abstract][Full Text] [Related]
4. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
[TBL] [Abstract][Full Text] [Related]
5. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: A comparative real-life study.
Pham THN; Schulze-Hagen MF; Rahnama'i MS
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1962. PubMed ID: 38217298
[TBL] [Abstract][Full Text] [Related]
6. Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies.
Maxeiner A; Nest AM; Stephan C; Cash H; Baur ADJ; Fischer T; Kilic E; Piper SK; Nowak CP; Busch J; Miller K; Mang J
Urol Int; 2020; 104(3-4):205-213. PubMed ID: 31801153
[TBL] [Abstract][Full Text] [Related]
7. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; van Melick HHE; Somford DM
Eur Urol Oncol; 2020 Apr; 3(2):216-223. PubMed ID: 31239236
[TBL] [Abstract][Full Text] [Related]
8. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance.
Borghesi M; Bianchi L; Barbaresi U; Vagnoni V; Corcioni B; Gaudiano C; Fiorentino M; Giunchi F; Chessa F; Garofalo M; Bertaccini A; Angelini S; Ercolino A; Casablanca C; Droghetti M; Golfieri R; Schiavina R
Minerva Urol Nephrol; 2021 Jun; 73(3):357-366. PubMed ID: 33769008
[TBL] [Abstract][Full Text] [Related]
10. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
11. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling.
Noujeim JP; Belahsen Y; Lefebvre Y; Lemort M; Deforche M; Sirtaine N; Martin R; Roumeguère T; Peltier A; Diamand R
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):575-580. PubMed ID: 36509930
[TBL] [Abstract][Full Text] [Related]
12. mpMRI-targeted biopsy versus systematic biopsy for clinically significant prostate cancer diagnosis: a systematic review and metaanalysis.
Baccaglini W; Glina FPA; Pazeto CL; Bernardo WM; Sanchez-Salas R
Curr Opin Urol; 2020 Sep; 30(5):711-719. PubMed ID: 32732624
[TBL] [Abstract][Full Text] [Related]
13. Value of perilesional biopsies in multiparametric magnetic resonance imaging-targeted biopsy and systematic biopsy in detection of prostate cancer: results of a prospective, non-randomized, surgeon-blinded study.
Duwe G; Schmitteckert M; Haack M; Sparwasser P; Dotzauer R; Thomas A; Tsaur I; Brandt MP; Kurosch M; Mager R; Haferkamp A; Boehm K; Höfner T
World J Urol; 2024 May; 42(1):297. PubMed ID: 38709326
[TBL] [Abstract][Full Text] [Related]
14. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
[TBL] [Abstract][Full Text] [Related]
15. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.
Freifeld Y; Xi Y; Passoni N; Woldu S; Hornberger B; Goldberg K; Bagrodia A; Raj G; Margulis V; Cadeddu JA; Lotan Y; Francis F; Pedrosa I; G Roehrborn C; Costa DN
Urol Oncol; 2019 Jan; 37(1):57-62. PubMed ID: 30446460
[TBL] [Abstract][Full Text] [Related]
16. Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy.
Hansen NL; Barrett T; Lloyd T; Warren A; Samel C; Bratt O; Kastner C
BJU Int; 2020 Feb; 125(2):260-269. PubMed ID: 31306539
[TBL] [Abstract][Full Text] [Related]
17. Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography-fusion Biopsy.
Tschirdewahn S; Wiesenfarth M; Bonekamp D; Püllen L; Reis H; Panic A; Kesch C; Darr C; Heß J; Giganti F; Moore CM; Guberina N; Forsting M; Wetter A; Hadaschik B; Radtke JP
Eur Urol Focus; 2021 Nov; 7(6):1300-1307. PubMed ID: 32660838
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
[TBL] [Abstract][Full Text] [Related]
19. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?
Günzel K; Magheli A; Busch J; Baco E; Cash H; Heinrich S; Edler D; Schostak M; Borgmann H; Schlegel J; Hinz S
Int Urol Nephrol; 2022 Oct; 54(10):2477-2483. PubMed ID: 35877030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
